Evidence method
Level · gp.fundamentals.debt_to_revenue
62.43% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
PBYI · Sep 30, 2025
PUMA BIOTECHNOLOGY, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001437749-25-033633General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.05% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
17.79% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-32.36% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
17.40% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
77.65% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
17.57% · CORE · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
3.07% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History13 statesHistory building
Jun 30, 20230/5 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20240/8 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20255/8 normalizedLevel 3Sep 30, 20256/8 normalizedLevel 3Dec 31, 20256/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 86.47%
- Current
- 62.43%
- Delta
- -24.04%
- Previous
- 0.04%
- Current
- 0.05%
- Delta
- 0.01%
- Previous
- 26.86%
- Current
- 17.79%
- Delta
- -9.07%
- Previous
- 11.37%
- Current
- -32.36%
- Delta
- -43.73%
- Previous
- 16.38%
- Current
- 17.40%
- Delta
- 1.01%
- Previous
- 76.54%
- Current
- 77.65%
- Delta
- 1.11%
- Previous
- 12.66%
- Current
- 17.57%
- Delta
- 4.92%
- Previous
- 3.10%
- Current
- 3.07%
- Delta
- -0.03%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · PBYI Fundamental State →Has State · PUMA BIOTECHNOLOGY, INC. →Transitioned To · PBYI Fundamental State →Transitioned To · PBYI BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · PBYI CAPEX_INTENSITY_INCREASED →Transitioned To · PBYI CASH_GENERATION_DECREASED →Transitioned To · PBYI GROWTH_DECREASED →Transitioned To · PBYI INVENTORY_PRESSURE_INCREASED →Transitioned To · PBYI MARGIN_INCREASED →Transitioned To · PBYI PROFITABILITY_INCREASED →Transitioned To · PBYI SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.